Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026226 | 1.00 | TAS2R14 (0.46) | TAS2R14MCHR1LIMK2CNR2MAPT | |
| SCHEMBL28600697 | 0.88 | TAS2R14 (0.44) | TAS2R14MCHR1LIMK2CNR2MAPT | |
| SCHEMBL29104391 | 0.82 | EPOR (0.49) | TAS2R14MCHR1LIMK2CNR2MAPT | |
| SCHEMBL28403514 | 0.82 | CPA1 (0.50) | ALDH1A1POLBLMNA | |
| SCHEMBL2287044 | 0.82 | CPA1 (0.50) | ALDH1A1POLBLMNA | |
| SCHEMBL6703919 | 0.82 | CPA1 (0.50) | ALDH1A1POLBLMNA | |
| Hydrochloric Acid SCHEMBL14874679 | 0.81 | CPA1 (0.49) | MCHR1ALDH1A1POLBLMNANPSR1 | |
| SCHEMBL3458080 | 0.79 | BACE1 (0.40) | TAS2R14MCHR1LIMK2CNR2ALDH1A1 | |
| SCHEMBL6024693 | 0.79 | BACE1 (0.40) | TAS2R14MCHR1LIMK2CNR2ALDH1A1 | |
| SCHEMBL6024628 | 0.79 | BACE1 (0.40) | TAS2R14MCHR1LIMK2CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107353409-B | Dendritic polymer compound and preparation method and application thereof | 安徽丰原药业股份有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-107353409-B | Dendritic polymer compound and preparation method and application thereof | 安徽丰原药业股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-2797900-B1 | COMPLEX-FORMING COMPOUNDS | STRATOXER S KFT (HU) | 2016-09-28 | — | — | EP | disclosed |
| US-9243031-B2 | Complex-forming compounds | STRATOXER(S) KFT. (HU) | 2016-01-26 | — | — | US | disclosed |
| US-20140342997-A1 | COMPLEX-FORMING COMPOUNDS | STRATOXER(S) KFT. (HU) | 2014-11-20 | — | — | US | disclosed |
| EP-2797900-A1 | COMPLEX-FORMING COMPOUNDS | Stratoxer(S) Kft. (HU) | 2014-11-05 | — | — | EP | disclosed |
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20140142167-A1 | Micellar Preparation Containing Sparingly Water-Soluble Anticancer Agent And Novel Block Copolymer | NANOCARRIER KABUSHIKI KAISHA (JP) | 2014-05-22 | — | — | US | disclosed |
| WO-2013098572-A1 | COMPLEX-FORMING COMPOUNDS | STRATOXER(S) KFT. (HU) | 2013-07-04 | — | — | WO | disclosed |
| US-7820759-B2 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20090156742-A1 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer | NANOCARRIER KABUSHIKI KAISHA (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-2019834-A1 | ECTONUCLEOTIDASE INHIBITORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007135195-A1 | ECTONUCLEOTIDASE INHIBITORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2007-11-29 | — | — | WO | disclosed |
| US-20060099265-A1 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer | NANOCARRIER KABUSHIKI KAISHA (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1604687-A1 | MICELLAR PREPARATION CONTAINING SPARINGLY WATER-SOLUBLE ANTICANCER AGENT AND NOVEL BLOCK COPOLYMER | Nippon Kayaku Kabushiki Kaisha (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-5578725-A | NARCOTIC PEPTIDES FOR CENTRAL NERVOUS SYSTEM DISORDERS AND AUTOIMMUNE DISEASES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996023793-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0458519-A2 | Synthesis of nucleotide and nucleoside derivatives | EFAMOL HOLDINGS PLC (GB) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142167-A1 | Micellar Preparation Containing Sparingly Water-Soluble Anticancer Agent And Novel Block Copolymer | FLT1, NGLY1, CXCR1 | OPRM1 799/4885TAS2R14 3663/4885MCHR1 65/4885 |
| US-20060099265-A1 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer | FLT1, NGLY1, SLC7A1 | OPRM1 1198/4885TAS2R14 3751/4885MCHR1 77/4885 |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | OPRM1 894/4885TAS2R14 3792/4885MCHR1 2828/4885 |
| US-20140342997-A1 | COMPLEX-FORMING COMPOUNDS | F2, CYP2F1, CYP4F2 | OPRM1 2345/4885TAS2R14 2639/4885MCHR1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.